Shuiying Hu

Shuiying Hu Photograph

Shuiying Hu

Assistant Professor
Unit / Department / Division
Outcomes and Translational Sciences
406 Biomedical Research Tower
Email Address

Professional Interests

Professional Interests

Dr. Hu’s research interests include drug development and translational cancer pharmacology, and her current projects are focused on the development of transport modulators that could be used in conjunction with neurotoxic chemotherapy. The overall goal of her research is to evaluate the role of solute carriers in cancer drug-induced toxicity profiles, in particular peripheral neuropathy. In addition, she aims to identify chemical inhibitors of critical transporters, and explore novel strategies to ameliorate the incidence and severity of debilitating side effects of cancer drugs.


  • PhD, Pharmaceutical Sciences, West Virginia University


  • Dean's Innovative Research Award, 2019
  • American Society of Clinical Pharmacology and Therapeutics (ASCPT) Darrell Abernethy Early Stage Investigator Award, 2021

Journal Articles

Uddin ME, Moseley A, Hu S, Sparreboom A. Contribution of Membrane Transporters to Chemotherapy-Induced Cardiotoxicity. Basic Clin Pharmacol Toxicol. 2021 Jul 8. doi: 10.1111/bcpt.13635. Epub ahead of print. PMID: 34237188.

Marie S, Hernández-Lozano I, Breuil L, Truillet C, Hu S, Sparreboom A, Tournier N, Langer O. Imaging-Based Characterization of a <i>Slco2b1(-/-)</i> Mouse Model Using [<sup>11</sup>C]Erlotinib and [<sup>99m</sup>Tc]Mebrofenin as Probe Substrates. Pharmaceutics. 2021 Jun 21;13(6):918. doi: 10.3390/pharmaceutics13060918. PMID: 34205780; PMCID: PMC8233734.

Jin Y, Li Y, Uddin ME, Sparreboom A, Hu S. Rapid quantification of vincristine in mouse plasma using ESI-LC-MS/MS: Application to pharmacokinetic studies. J Chromatogr B Analyt Technol Biomed Life Sci. 2021 Apr 1;1168:122591. doi: 10.1016/j.jchromb.2021.122591. Epub 2021 Feb 21. PMID: 33684722; PMCID: PMC7987214.

Uddin ME, Garrison DA, Kim K, Jin Y, Eisenmann ED, Huang KM, Gibson AA, Hu Z, Sparreboom A, Hu S. Influence of YES1 Kinase and Tyrosine Phosphorylation on the Activity of OCT1. Front Pharmacol. 2021 Mar 8;12:644342. doi: 10.3389/fphar.2021.644342. PMID: 33790797; PMCID: PMC8006202.

Hayden ER, Chen M, Pasquariello KZ, Gibson AA, Petti JJ, Shen S, Qu J, Ong SS, Chen T, Jin Y, Uddin ME, Huang KM, Paz A, Sparreboom A, Hu S, Sprowl JA. Regulation of OATP1B1 Function by Tyrosine Kinase-mediated Phosphorylation. Clin Cancer Res. 2021 Mar 4. doi: 10.1158/1078-0432.CCR-21-0023. Epub ahead of print. PMID: 33664059.

Stage TB, Hu S, Sparreboom A, Kroetz DL. Role for Drug Transporters in Chemotherapy-Induced Peripheral Neuropathy. Clin Transl Sci. 2021 Mar;14(2):460-467. doi: 10.1111/cts.12915. Epub 2020 Nov 9. PMID: 33142018; PMCID: PMC7993259.

Li Y, Lustberg MB, Hu S. Emerging Pharmacological and Non-Pharmacological Therapeutics for Prevention and Treatment of Chemotherapy-Induced Peripheral Neuropathy. Cancers (Basel). 2021 Feb 12;13(4):766. doi: 10.3390/cancers13040766. PMID: 33673136; PMCID: PMC7918689.

Huang KM, Zavorka Thomas M, Magdy T, Eisenmann ED, Uddin ME, DiGiacomo DF, Pan A, Keiser M, Otter M, Xia SH, Li Y, Jin Y, Fu Q, Gibson AA, Bonilla IM, Carnes CA, Corps KN, Coppola V, Smith SA, Addison D, Nies AT, Bundschuh R, Chen T, Lustberg MB, Wang J, Oswald S, Campbell MJ, Yan PS, Baker SD, Hu S, Burridge PW, Sparreboom A. Targeting OCT3 attenuates doxorubicin-induced cardiac injury. Proc Natl Acad Sci U S A. 2021 Feb 2;118(5):e2020168118. doi: 10.1073/pnas.2020168118. PMID: 33495337; PMCID: PMC7865186.

Buelow DR, Anderson JT, Pounds SB, Shi L, Lamba JK, Hu S, Gibson AA, Goodwin EA, Sparreboom A, Baker SD. DNA Methylation-Based Epigenetic Repression of SLC22A4 Promotes Resistance to Cytarabine in Acute Myeloid Leukemia. Clin Transl Sci. 2021 Jan;14(1):137-142. doi: 10.1111/cts.12861. Epub 2020 Sep 9. PMID: 32905646; PMCID: PMC7877866.

Huang KM, Hu S. Targeting drug transporters to prevent chemotherapy-induced peripheral neuropathy. Mol Cell Oncol. 2020 Dec 1;8(1):1838863. doi: 10.1080/23723556.2020.1838863. PMID: 33553600; PMCID: PMC7849748.

Huang KM, Leblanc AF, Uddin ME, Kim JY, Chen M, Eisenmann ED, Gibson AA, Li Y, Hong KW, DiGiacomo D, Xia SH, Alberti P, Chiorazzi A, Housley SN, Cope TC, Sprowl JA, Wang J, Loprinzi CL, Noonan A, Lustberg MB, Cavaletti G, Pabla N, Hu S, Sparreboom A. Neuronal uptake transporters contribute to oxaliplatin neurotoxicity in mice. J Clin Invest. 2020 Sep 1;130(9):4601-4606. doi: 10.1172/JCI136796. PMID: 32484793; PMCID: PMC7456253.

Anderson JT, Huang KM, Lustberg MB, Sparreboom A, Hu S. Solute Carrier Transportome in Chemotherapy-Induced Adverse Drug Reactions. Rev Physiol Biochem Pharmacol. 2020 Aug 7:10.1007/112_2020_30. doi: 10.1007/112_2020_30. Epub ahead of print. PMID: 32761456; PMCID: PMC7902122.

Huang KM, Uddin ME, DiGiacomo D, Lustberg MB, Hu S, Sparreboom A. Role of <i>SLC</i> transporters in toxicity induced by anticancer drugs. Expert Opin Drug Metab Toxicol. 2020 Jun;16(6):493-506. doi: 10.1080/17425255.2020.1755253. Epub 2020 Apr 26. PMID: 32276560; PMCID: PMC7512084.

Chen M, Hu S, Li Y, Gibson AA, Fu Q, Baker SD, Sparreboom A. Role of Oatp2b1 in Drug Absorption and Drug-Drug Interactions. Drug Metab Dispos. 2020 May;48(5):419-425. doi: 10.1124/dmd.119.090316. Epub 2020 Feb 29. Erratum in: Drug Metab Dispos. 2020 Jun;48(6):446. PMID: 32114507; PMCID: PMC7180048.

Dwivedi P, Han S, Mangrio F, Fan R, Dwivedi M, Zhu Z, Huang F, Wu Q, Khatik R, Cohn DE, Si T, Hu S, Sparreboom A, Xu RX. Corrigendum to "Engineered multifunctional biodegradable hybrid microparticles for paclitaxel delivery in cancer therapy" [Mater Sci Eng C 102 (2019) 113-123]. Mater Sci Eng C Mater Biol Appl. 2020 Mar;108:110326. doi: 10.1016/j.msec.2019.110326. Epub 2019 Nov 20. Erratum for: Mater Sci Eng C Mater Biol Appl. 2019 Sep;102:113-123. PMID: 31924044.

Guo S, Vieweger M, Zhang K, Yin H, Wang H, Li X, Li S, Hu S, Sparreboom A, Evers BM, Dong Y, Chiu W, Guo P. Ultra-thermostable RNA nanoparticles for solubilizing and high-yield loading of paclitaxel for breast cancer therapy. Nat Commun. 2020 Feb 20;11(1):972. doi: 10.1038/s41467-020-14780-5. PMID: 32080195; PMCID: PMC7033104.

Chen M, Neul C, Schaeffeler E, Frisch F, Winter S, Schwab M, Koepsell H, Hu S, Laufer S, Baker SD, Sparreboom A, Nies AT. Sorafenib Activity and Disposition in Liver Cancer Does Not Depend on Organic Cation Transporter 1. Clin Pharmacol Ther. 2020 Jan;107(1):227-237. doi: 10.1002/cpt.1588. Epub 2019 Sep 3. PMID: 31350763; PMCID: PMC6925656.